Skip to main content
SpringerLink
Log in

Nampt and Its Potential Role in Inflammation and Type 2 Diabetes

  • Chapter
  • First Online:
Diabetes - Perspectives in Drug Therapy

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 203))

Abstract

Nicotinamide phosphoribosyltransferase (Nampt ) is a key nicotinamide adenine dinucleotide (NAD) biosynthetic enzyme in mammals, converting nicotinamide into nicotinamide mononucleotide (NMN ), an NAD intermediate. First identified in humans as a cytokine pre-B-cell colony enhancing factor (PBEF ) and subsequently described as an insulin-mimetic hormone visfatin , Nampt has recently excited the scientific interest of researchers from diverse fields, including NAD biology, metabolic regulation, and inflammation. As an NAD biosynthetic enzyme, Nampt regulates the activity of NAD-consuming enzymes such as sirtuins and influences a variety of metabolic and stress responses. Nampt plays an important role in the regulation of insulin secretion in pancreatic β-cells. Nampt also functions as an immunomodulatory cytokine and is involved in the regulation of inflammatory responses. This chapter summarizes the various functional aspects of Nampt and discusses its potential roles in diseases, with special focus on type 2 diabetes mellitus (T2DM).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adya R, Tan BK, Chen J, Randeva HS (2008) Nuclear factor B induction by visfatin in human vascular endothelial cells: role in MMP-2/9 production and activation{kappa}. Diab Care 31:758–760

    CAS  Google Scholar 

  • Alghasham AA, Barakat YA (2008) Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy . Saudi Med J 29:185–192

    PubMed  Google Scholar 

  • Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC (2009) Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease . Dig Dis Sci 54:1772–1777

    CAS  PubMed  Google Scholar 

  • Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y, Asayama K, Shirahata A (2008) Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children . Obesity (Silver Spring) 16:384–388

    CAS  Google Scholar 

  • Arner P (2006) Visfatin - a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 91:28–30

    CAS  PubMed  Google Scholar 

  • Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Pérusse L, Vohl MC, Engert JC (2006) Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population . Diabetes 55:2896–2902

    CAS  PubMed  Google Scholar 

  • Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans . Diabetes 54:2911–2916

    CAS  PubMed  Google Scholar 

  • Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417–435

    CAS  PubMed  Google Scholar 

  • Brown JE, Onyango DJ, Ramanjaneya M, Conner AC, Patel ST, Dunmore SJ, Randeva HS (2010) Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells . J Mol Endocrinol 44:171–178

    CAS  PubMed  Google Scholar 

  • Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, DeSmedt T (2008) Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3:e2267

    PubMed Central  PubMed  Google Scholar 

  • Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Cienfuegos JA, Salvador J, Frühbeck G (2010) Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity . Nutr Metab Cardiovasc Dis. doi:10.1016/j.numecd.2009.09.008

    PubMed  Google Scholar 

  • Caton PW, Nayuni N, Kieswich J, Khan N, Yaqoob M, Corder R (2010) Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 205:97–106

    CAS  PubMed  Google Scholar 

  • Chang AM, Halter JB (2003) Aging and insulin secretion . Am J Physiol Endocrinol Metab 284:E7–E12

    CAS  PubMed  Google Scholar 

  • Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, Lai MM, Lin CC (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56(9):1216–1220

    CAS  PubMed  Google Scholar 

  • Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus . J Clin Endocrinol Metab 91:295–299

    CAS  PubMed  Google Scholar 

  • Cheng KH, Chu CS, Lee KT, Lin TH, Hsieh CC, Chiu CC, Voon WC, Sheu SH, Lai WT (2008) Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32(2):268–274

    CAS  Google Scholar 

  • Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM (2007) Effect of exercise training on plasma visfatin and eotaxin levels . Eur J Endocrinol 157:437–442

    CAS  PubMed  Google Scholar 

  • Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG (2008) Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease . Eur J Endocrinol 158:203–207

    CAS  PubMed  Google Scholar 

  • Corda D, Di Girolamo M (2003) Functional aspects of protein mono-ADP-ribosylation. EMBO J 22:1953–1958

    PubMed Central  CAS  PubMed  Google Scholar 

  • Coskun A, Ozkaya M, Kiran G, Kilinc M, Arikan DC (2010) Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus . J Matern Fetal Neonatal Med 23:1014–1018

    CAS  PubMed  Google Scholar 

  • Dahl TB, Ynestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization . Circulation 115:972–980

    CAS  PubMed  Google Scholar 

  • de Boer JF, Bahr MJ, Böker KH, Manns MP, Tietge UJ (2009) Plasma levels of PBEF/Nampt/ visfatin are decreased in patients with liver cirrhosis . Am J Physiol Gastrointest Liver Physiol 296:G196–G210

    PubMed  Google Scholar 

  • de Kreutzenberg SV, Ceolotto G, Papparella I, Bortoluzzi A, Semplicini A, Dalla Man C, Cobelli C, Fadini GP, Avogaro A (2010) Downregulation of the longevity-associated protein SIRT1 in insulin resistance and metabolic syndrome. Potential biochemical mechanisms. Diabetes 59:1006–1015

    PubMed Central  PubMed  Google Scholar 

  • de Luis DA, Sagrado MG, Conde R, Aller R, Izaola O (2009) Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose . Nutrition. doi:10.1016/j.nut.2008.11.005

    Google Scholar 

  • Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H (2008) Serum levels of the adipokine visfatin are increased in preeclampsia . Clin Endocrinol (Oxf) 69:69–73

    CAS  Google Scholar 

  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430

    CAS  PubMed  Google Scholar 

  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2007) Retraction. Science 318:565

    CAS  PubMed  Google Scholar 

  • García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL, Rojo-Martínez G, Garrido-Sánchez L, Bermudez-Silva FJ, Rodríguez de Fonseca F, Soriguer F (2007) Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass . Obesity (Silver Spring) 15:2391–2395

    Google Scholar 

  • Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler W, Kratzsch J, Kiess W, Gebhardt R (2010) Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes . Biochem Biophys Res Commun 391:376–381

    CAS  PubMed  Google Scholar 

  • Gok DE, Yazici M, Uckaya G, Bolu SE, Basaran Y, Ozgurtas T, Kilic S, Kutlu M (2010) The role of visfatin in the pathogenesis of gestational diabetes mellitus. J Endocrinol Invest. doi:10.3275/6902

    PubMed  Google Scholar 

  • Guarente L (2005) Calorie restriction and Sir2 genes – towards a mechanism. Mech Ageing Dev 126:923–928

    CAS  PubMed  Google Scholar 

  • Guest CB, Park MJ, Johnson DR, Freund GG (2008) The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 13:5187–5194

    CAS  PubMed  Google Scholar 

  • Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H (2009) Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans . Diabetes 58:637–640

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63:7436–7442

    CAS  PubMed  Google Scholar 

  • Haus JM, Solomon TP, Marchetti CM, O’Leary VB, Brooks LM, Gonzalez F, Kirwan JP (2009) Decreased visfatin after exercise training correlates with improved glucose tolerance . Med Sci Sports Exerc 41:1255–1260

    CAS  PubMed  Google Scholar 

  • Hayashida S, Arimoto A, Kuramoto Y, Kozako T, Honda SI, Shimeno H, Soeda S (2010) Fasting promotes the expression of SIRT1, an NAD(+)-dependent protein deacetylase, via activation of PPARalpha in mice . Mol Cell Biochem 339:285–292

    CAS  PubMed  Google Scholar 

  • Hofsø D, Ueland T, Hager H, Jenssen T, Bollerslev J, Godang K, Aukrust P, Røislien J, Hjelmesaeth J (2009) Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol 161:451–458

    PubMed  Google Scholar 

  • Hug C, Lodish HF (2005) Medicine. Visfatin: a new adipokine. Science 307:366–367

    CAS  PubMed  Google Scholar 

  • Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase . Nature 403:795–800

    CAS  PubMed  Google Scholar 

  • Imai S, Kiess W (2009) Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes . Front Biosci 14:2983–2995

    CAS  Google Scholar 

  • Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis . J Clin Invest 113:1318–1327

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M (2008) Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol . Diabetes Res Clin Pract 79:412–418

    CAS  PubMed  Google Scholar 

  • Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I, Karkos C, Karayannacos PE, Gerasimidis T, Liapis CD (2010) Visfatin (Nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes . Exp Clin Endocrinol Diabetes 118:75–80

    CAS  PubMed  Google Scholar 

  • Kaeberlein M, McVey M, Guarente L (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13:2570–2580

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD (2008) Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/Visfatin) expression and protects them from apoptosis . Placenta 29:255–265

    CAS  PubMed  Google Scholar 

  • Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13:582–588

    CAS  PubMed  Google Scholar 

  • Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, Lee YS, Kim JB, Kim KK, Suh SW, Eom SH (2006) Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866 . J Mol Biol 362:66–77

    CAS  PubMed  Google Scholar 

  • Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays . J Clin Endocrinol Metab 92:4783–4791

    PubMed  Google Scholar 

  • Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, Krone W (2010) Visfatin/PBEF/Nampt and Resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans . Horm Metab Res 42:268–273

    CAS  PubMed  Google Scholar 

  • Leclercq IA, Da Silva MA, Schroyen B, Van Hul N, Geerts A (2007) Insulin resistance in hepatocyte sand sinusoidal liver cells: mechanisms and consequences. J Hepatol 47:142–156

    CAS  PubMed  Google Scholar 

  • Lee HC (2001) Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol 41:317–345

    PubMed  Google Scholar 

  • Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, Woo CW, Brunkan CS, Wolberger C, Imai SI, Tabas I (2008) Extracellular Nampt promotes macrophage survival via a non-enzymatic interleukin-6/STAT3 signaling mechanism . J Biol Chem 283:34833–34843

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lin SJ, Guarente L (2003) Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol 15:241–246

    CAS  PubMed  Google Scholar 

  • Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity . J Leukoc Biol 83:804–816

    CAS  PubMed  Google Scholar 

  • Magni G, Amici A, Emanuelli M, Ruggieri S (1999) Enzymology of NAD+ synthesis . Adv Enzymol Relat Areas Mol Biol 73:135–182

    CAS  PubMed  Google Scholar 

  • Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, Corsi MM, Ambrosi B (2008) Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity . Nutr Metab Cardiovasc Dis 18:523–530

    CAS  PubMed  Google Scholar 

  • Martin P, Shea RJ, Mulks MH (2001) Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence . J Bacteriol 183:1168–1174

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ménissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Amé JC, Dierich A, LeMeur M, Sabatier L, Chambon P, de Murcia G (2003) Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 22:2255–2263

    PubMed Central  PubMed  Google Scholar 

  • Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bernis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliot PJ, Westphal CH (2007) Small molecule activators of Sirt1 as therapeutics for the treatment of type 2 diabetes . Nature 450:712–716

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mirzaei K, Hossein-Nezhad A, Javad Hosseinzadeh-Attar M, Jafari N, Najmafshar A, Mohammadzadeh N, Larijani B (2009) Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients. Minerva Endocrinol 34:273–279

    CAS  PubMed  Google Scholar 

  • Moller N, Gormsen L, Fuglsang J, Gjedsted J (2003) Effects of ageing on insulin secretion and action . Horm Res 60:102–104

    CAS  PubMed  Google Scholar 

  • Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H (2007) Visfatin, an adipocytokine with antiinflammatory and immunomodulating properties. J Immunol 178:1748–1758

    CAS  PubMed  Google Scholar 

  • Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, Ebenbichler CF, Stadlmann S, Moser PL, Tilg H (2009) Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 51:765–777

    CAS  PubMed  Google Scholar 

  • Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, Permutt MA, Imai S (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice . Cell Metab 2:80–82

    Google Scholar 

  • Nüsken KD, Nüsken E, Petrasch M, Rauh M, Dötsch J (2007) Preanalytical influences on the measurement of visfatin by enzyme immuno assay . Clin Chim Acta 382:154–156

    PubMed  Google Scholar 

  • Nüsken KD, Petrasch M, Rauh M, Stöhr W, Nüsken E, Schneider H, Dötsch J (2009) Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol . Nephrol Dial Transplant 24:2832–2838

    PubMed  Google Scholar 

  • Ognjanovic S, Bryant-Greenwood GD (2002) Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes . Am J Obstet Gynecol 187:1051–1058

    CAS  PubMed  Google Scholar 

  • Ognjanovic S, Ku TL, Bryant-Greenwood GD (2005) Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium . Am J Obstet Gynecol 193:273–282

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans . J Clin Endocrinol Metab 91:3165–3170

    CAS  PubMed  Google Scholar 

  • Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387(1–2):31–35

    CAS  PubMed  Google Scholar 

  • Pilz S, Mangge H, Obermayer-Pietsch B, März W (2007) Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 30:138–144

    CAS  PubMed  Google Scholar 

  • Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH (2006) Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. Circulation 113:898–918

    PubMed  Google Scholar 

  • Preiss J, Handler P (1957) Enzymatic synthesis of nicotinamide mononucleotide . J Biol Chem 225:759–770

    CAS  PubMed  Google Scholar 

  • Ramsey KM, Mills KF, Satoh A, Imai S (2008) Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice . Aging Cell 7:78–88

    PubMed Central  CAS  PubMed  Google Scholar 

  • Retnakaran R, Youn BS, Liu Y, Hanley AJG, Lee NS, Park JW, Song ES, Vu V, Kim W, Tungtrongchitr R, Havel PJ, Swarbrick MM, Shaw C, Sweeney G (2008) Correlation of circulating full-lenght visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study . Clin Endocrinol (Oxf) 69:885–893

    CAS  Google Scholar 

  • Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells . J Biol Chem 279:50754–50763

    CAS  PubMed  Google Scholar 

  • Revollo JR, Grimm AA, Imai S (2007a) The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals . Curr Opin Gastroenterol 23:164–170

    CAS  PubMed  Google Scholar 

  • Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S (2007b) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme . Cell Metab 6:363–375

    PubMed Central  CAS  PubMed  Google Scholar 

  • Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and Sirt1 . Nature 434:113–118

    CAS  PubMed  Google Scholar 

  • Rogina B, Helfand SL (2004) Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 101:15998–16003

    PubMed Central  CAS  PubMed  Google Scholar 

  • Romacho T, Azcutia V, Vázquez-Bella M, Matesanz N, Cercas E, Nevado J, Carraro R, Rodríguez-Mañas L, Sánchez-Ferrer CF, Peiró C (2009) Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity . Diabetologia 52:2455–2463

    CAS  PubMed  Google Scholar 

  • Rongvaux A, Andris F, Van Gool F, Leo O (2003) Reconstructing eukaryotic NAD metabolism . Bioessays 25:683–690

    CAS  PubMed  Google Scholar 

  • Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F (2002) Pre-B-cell colony enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis . Eur J Immunol 32:3225–3234

    CAS  PubMed  Google Scholar 

  • Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431–1437

    PubMed Central  CAS  PubMed  Google Scholar 

  • Schenk S, Saberi M, Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118:2992–3002

    PubMed Central  CAS  PubMed  Google Scholar 

  • Schwer B, Verdin E (2008) Conserved metabolic regulatory functions of sirtuins . Cell Metab 7:104–112

    CAS  PubMed  Google Scholar 

  • Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, Lee KW, Kim SG, Choi KM, Baik SH, Choi DS, Kim NH (2008) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women . Diabetes Res Clin Pract 79:108–111

    CAS  PubMed  Google Scholar 

  • Sethi JK (2007) Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? . Curr Hypertens Rep 9:33–38

    PubMed Central  CAS  PubMed  Google Scholar 

  • Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G, Brechlin AM, Schambach A, Hinrichsen L, Meyer G, Gaestel M, Stanulla M, Tong Q, Welte K (2009) NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway . Nat Med 15:151–158

    CAS  PubMed  Google Scholar 

  • Sommer G, Kralisch S, Kloting N, Kamprad M, Schrock K, Kratzsch J, Tonjes A, Lossner U, Bluher M, Stumvoll M, Fasshauer M (2010) Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 18:1486–1492

    CAS  Google Scholar 

  • Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, Han JY, Han SY, Han KH, Kim HK, Cha DR (2008) Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295:F1485–F1494

    CAS  PubMed  Google Scholar 

  • Sowers JR (2003) Obesity as a cardiovascular risk factor. Am J Med 115:37S–41S

    CAS  PubMed  Google Scholar 

  • Stephens JM, Vidal-Puig A (2006) An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity . Curr Opin Lipidol 17:128–131

    CAS  PubMed  Google Scholar 

  • Sun Q, Li L, Li R, Yang M, Liu H, Nowicki MJ, Zong H, Xu J, Yang G (2009) Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats . Ann Med 41:311–320

    CAS  PubMed  Google Scholar 

  • Szamatowicz J, Kužmicki M, Telejko B, Zonenberg A, Nikolajuk A, Kretowski A, Górska M (2009) Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes . Ginekol Pol 80:14–18

    PubMed  Google Scholar 

  • Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, Komuro R, Shimomura I (2007) Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 359:194–201

    CAS  PubMed  Google Scholar 

  • Telejko B, Kuzmicki M, Zonenberg A, Szamatowicz J, Wawrusiewicz-Kurylonek N, Nikolajuk A, Kretowski A, Gorska M (2009) Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 84:68–75

    CAS  PubMed  Google Scholar 

  • Tissenbaum HA, Guarente L (2001) Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410:227–230

    CAS  PubMed  Google Scholar 

  • Toruner F, Altinova AE, Bukan AE, Akbay E, Ersoy R, Arslan M (2009) Plasma visfatin concentrations in subjects with type 1 diabetes mellitus . Horm Res 72:33–37

    CAS  PubMed  Google Scholar 

  • Unluturk U, Harmanci A, Yildiz BO, Bayraktar M (2010) Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women . Clin Endocrinol (Oxf) 72:469–474

    CAS  PubMed  Google Scholar 

  • van der Veer E, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG (2005) Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation . Circ Res 97:25–34

    PubMed  Google Scholar 

  • Wang P, van Greevenbroek MM, Bouwman FG, Brouwers MC, van der Kallen CJ, Smit E, Keijer J, Mariman EC (2007) The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile . Pflugers Arch 454:971–976

    CAS  PubMed  Google Scholar 

  • Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C (2006) Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme . Nat Struct Mol Biol 13:661–662

    CAS  PubMed  Google Scholar 

  • Westphal CH, Dipp MA, Guarente L (2008) A therapeutic role of sirtuins in diseases of aging? Trends Biochem Sci 32:555–560

    Google Scholar 

  • Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY (2007) Insulin-like effects of visfatin on human osteoblasts . Calcif Tissue Int 80:201–210

    CAS  PubMed  Google Scholar 

  • Xu LG, Wu M, Hu J, Zhai Z, Shu HB (2002) Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 72:410–416

    CAS  PubMed  Google Scholar 

  • Yang H, Lavu S, Sinclair DA (2006) Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol 41:718–726

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z, Kirazli S, Yarali H (2010) Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online 20:150–155

    CAS  PubMed  Google Scholar 

  • Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J (2008) Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 23:1621–1627

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Leipzig, Hospital for Children and Adolescents, Liebigstr. 20a, 04103, Leipzig, Germany

    Antje Garten, Stefanie Petzold, Susanne Schuster, Antje Körner & Wieland Kiess

  2. Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Paul-List-Str.13a, 04103, Leipzig, Germany

    Jürgen Kratzsch

Authors
  1. Antje Garten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefanie Petzold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antje Körner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Kratzsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wieland Kiess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wieland Kiess .

Editor information

Editors and Affiliations

  1. Fakultät Lebenswissenschaften Molekulare Pharmakologie und Toxikologie, Technische Universität Braunschweig, Beethovenstraße 55, 38106, Braunschweig, Germany

    Mathias Schwanstecher

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Garten, A., Petzold, S., Schuster, S., Körner, A., Kratzsch, J., Kiess, W. (2011). Nampt and Its Potential Role in Inflammation and Type 2 Diabetes. In: Schwanstecher, M. (eds) Diabetes - Perspectives in Drug Therapy. Handbook of Experimental Pharmacology, vol 203. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17214-4_7

Download citation

Publish with us

Policies and ethics

Search

Navigation